Akari Therapeutics
AKTX
8 hedge funds and large institutions have $11.5M invested in Akari Therapeutics in 2014 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.
14% more funds holding
Funds holding: 7 → 8 (+1)
12% less capital invested
Capital invested by funds: $13.1M → $11.5M (-$1.6M)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$306K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.79M |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
-$87.6K |
| 3 |
PCM
Prelude Capital Management
New York
|
-$15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Franklin Resources
San Mateo,
California
| $3.37M | – | – | – |
|
|
BBA
2
Baker Bros. Advisors
New York
| $3.23M | – | – | – |
|
|
BC
3
Broadfin Capital
New York
| $2.26M | – | – | – |
|
|
CAM
4
Cormorant Asset Management
Boston,
Massachusetts
| $1.44M | +$306K | +7 | +23% |
|
|
SCM
5
Sio Capital Management
New York
| $881K | +$1.01M | +23 | New |
|
|
DCM
6
DAFNA Capital Management
Los Angeles,
California
| $211K | – | – | – |
|
|
7
HighTower Advisors
Chicago,
Illinois
| $66K | -$87.6K | -2 | -50% |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $3K | – | – | – |
|
|
SM
9
Sabby Management
Miami Beach,
Florida
| $2.59K | -$1.79M | -41 | -38% |
|
10
Citigroup
New York
| $1K | – | – | – |
|
|
PCM
11
Prelude Capital Management
New York
| – | -$15K | – | – |
|
AKTX Hedge Fund Activity: Q4 2014 in Review
8 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q4 2014, worth a combined $11.5M — down 12% from $13.1M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new AKTX positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Cormorant Asset Management, adding an estimated $306K. The largest seller was Sabby Management, cutting an estimated $1.79M.
- 8 institutional investors held Akari Therapeutics (AKTX) as of Q4 2014, up from 7 in Q3 2014.
- Funds reported $11.5M of Akari Therapeutics stock for Q4 2014, down 12% quarter-over-quarter.
- 1 fund opened new Akari Therapeutics positions in Q4 2014 and 0 closed out, a net change of +1 holder.
- The largest Akari Therapeutics buyer in Q4 2014 was Cormorant Asset Management, an estimated $306K added.
- The largest Akari Therapeutics seller in Q4 2014 was Sabby Management, an estimated $1.79M sold.
Based on aggregated 13F filings for Q4 2014.